Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887797 | 0.91 | SMPD1 (0.46) | SMPD1ALDH1A1HRH3NOTUM | |
| SCHEMBL14228524 | 0.86 | SMPD1 (0.47) | SMPD1ALDH1A1HRH3CYP19A1CYP1A2 | |
| SCHEMBL26928299 | 0.84 | NOTUM (0.44) | SMPD1ALDH1A1NOTUM | |
| SCHEMBL6128431 | 0.83 | SMPD1 (0.44) | SMPD1ALDH1A1HRH3CYP19A1CYP1A2 | |
| SCHEMBL10288677 | 0.80 | SMPD1 (0.43) | SMPD1ALDH1A1HRH3CYP19A1CYP1A2 | |
| SCHEMBL11923794 | 0.79 | SMPD1 (0.42) | SMPD1ALDH1A1HRH3CYP19A1CYP1A2 | |
| SCHEMBL7303479 | 0.79 | NOTUM (0.43) | HRH3NOTUM | |
| SCHEMBL25602002 | 0.77 | SMPD1 (0.47) | SMPD1ALDH1A1CYP19A1CYP1A2CYP2C9 | |
| SCHEMBL15871987 | 0.77 | SMPD1 (0.48) | SMPD1ALDH1A1CYP19A1CYP1A2CYP2C9 | |
| SCHEMBL17122452 | 0.76 | SMPD1 (0.43) | SMPD1ALDH1A1HRH3CYP19A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138831-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | President and Fellows of Harvard College (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20160340325-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-24 | — | — | US | disclosed |
| EP-3056487-A1 | SYNTHESIS OF ENONE INTERMEDIATE | President and Fellows of Harvard College (US) | 2016-08-17 | — | — | EP | disclosed |
| US-9365493-B2 | Synthesis of tetracyclines and analogues thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2487160-B1 | Synthesis of Enone Intermediate | HARVARD COLLEGE (US) | 2016-02-03 | — | — | EP | disclosed |
| EP-2590944-B1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-09-30 | — | — | EP | disclosed |
| US-8907104-B2 | Synthesis of enone intermediate | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-12-09 | — | — | US | disclosed |
| EP-2479169-B1 | Synthesis of Enone Intermediate | HARVARD COLLEGE (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20140179929-A1 | SYNTHESIS OF ENONE INTERMEDIATE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140163238-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2479169-A1 | Synthesis of Enone Intermediate | President and Fellows of Harvard College (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20120029199-A1 | SYNTHESIS OF ENONE INTERMEDIATE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-02-02 | — | — | US | disclosed |
| US-7960559-B2 | Synthesis of enone intermediate | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110009639-A1 | SYNTHESIS OF ENONE INTERMEDIATE | MYERS ANDREW G | 2011-01-13 | — | — | US | disclosed |
| US-20110009371-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| US-7807842-B2 | Synthesis of tetracyclines and analogues thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-10-05 | — | — | US | disclosed |
| US-7763735-B2 | modular synthesis of tetracycline analogs through a chiral enone intermediate; efficiency | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-07-27 | — | — | US | disclosed |
| US-20100130451-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2010-05-27 | — | — | US | disclosed |
| US-20090093640-A1 | modular synthesis of tetracycline analogs through a chiral enone intermediate; efficiency | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-09 | — | — | US | disclosed |
| WO-2008127361-A2 | SYNTHESIS OF ENONE INTERMEDIATE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163238-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | TET1, TET3, MYC | SMPD1 4444/4885ALDH1A1 4455/4885HRH3 3556/4885 |
| US-20110009639-A1 | SYNTHESIS OF ENONE INTERMEDIATE | TECR, ECI1, ERAL1 | SMPD1 4418/4885ALDH1A1 3547/4885HRH3 4112/4885 |
| US-20090093640-A1 | modular synthesis of tetracycline analogs through a chiral enone intermediate; efficiency | TECR, TSN, TARS2 | SMPD1 4683/4885ALDH1A1 4307/4885HRH3 4077/4885 |
| US-20100130451-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | CCNE1, CCNE2, CCNT2 | SMPD1 4492/4885ALDH1A1 4622/4885HRH3 3897/4885 |
| US-20110009371-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | TET1, TET3, MYC | SMPD1 4444/4885ALDH1A1 4455/4885HRH3 3556/4885 |
| US-20140179929-A1 | SYNTHESIS OF ENONE INTERMEDIATE | TECR, ECI1, ERAL1 | SMPD1 4418/4885ALDH1A1 3547/4885HRH3 4112/4885 |
| US-20120029199-A1 | SYNTHESIS OF ENONE INTERMEDIATE | TECR, ECI1, ERAL1 | SMPD1 4418/4885ALDH1A1 3547/4885HRH3 4112/4885 |
| US-20160340325-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | TET1, TET3, MYC | SMPD1 4444/4885ALDH1A1 4455/4885HRH3 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.